#glp-1-obesity-drugs

[ follow ]
#novo-nordisk #ozempicwegovy #drug-pipeline #fda-regulation #telehealth-advertising #compounded-drugs
from24/7 Wall St.
1 week ago

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Sept 2025)

With as much as $17 billion in sales in 2024 and over $10 billion in the first half of 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S ( NYSE: NVO). This Scandinavian economic behemoth is one of the highest-valued companies in Europe at over $500 billion, which exceeds Denmark's entire gross domestic product.
Business
Public health
fromBloomberglaw
2 weeks ago

FDA Chief Says Hims' Weight-Loss Drug Ad Breached Agency's Rules

FDA cites telehealth ads for compounded GLP‑1 obesity drugs that omit side effects and calls for stricter enforcement against misleading pharmaceutical advertising.
[ Load more ]